Order Polymers Here

Press Releases

Vista Veterinary Hospital has been awarded one of America’s Best Animal Hospitals 2025

The ranking of America’s Best Animal Hospitals recognizes the top 500 animal hospitals in the United States based on quality of care provided. To identify the top 500 animal hospitals, we conducted an extensive and thorough desk research effort to create a database of over 15,000 animal hospitals. We collected and analyzed more than 5 million customer ratings and reviews from social media for these animal hospitals from the last five years. The hospitals were evaluated in terms of their overall customer ratings and 8 key categories of service and facility quality.

Pictured left to right is Vivos Inc. Advisor Dr. Darryl Fisher, Vivos Inc. CEO Dr. Michael Korenko and Dr. Michelle Meyer from Vista Veterinary Hospital. Vista Veterinary Hospital in Kennewick, WA has been published by Newsweek and Plant-A Insights as being one of America’s Best Animal Hospitals 2025!

Read the Newsweek article here.

About the Author:

Michael Korenko
Michael Korenko
Dr. Michael Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defense. Dr. Korenko currently is the author of 28 patents and possesses extensive experience in nuclear applications. He is leading the Vivos Inc. team into treating cancer in animals and humans.
Next Post
Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025
Previous Post
Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024

IsoPet® is our division dedicated to treating cancers in animals using our patented Precision Radionuclide Therapy™ (PRnT). Our innovative approach in the treatment of cancerous tumors focuses on delivering targeted radiation directly to cancerous tumors in a single treatment while minimizing damage to surrounding healthy tissues.

Learn More

Deliver your active pharmaceutical with quick-dissolving, biodegradable thermogel consisting of poly(lactide-co-glycolide)-graft-poly(ethylene glycol). Initially developed at Pacific Northwest Laboratories and further refined by a collaboration between Vivos, Inc. and Akina, Inc.

Learn More

RadioGel® is our division dedicated to treating cancer in humans using our patented Precision Radionuclide Therapy™ (PRnT). RadioGel® is currently not approved for human use or commercial distribution in the United States. It is being studied under an FDA-approved Investigational Device Exemption (IDE) for clinical trials only.

Learn More
keyboard_arrow_up